Innoviva (INVA) Net Income towards Common Stockholders (2010 - 2026)
Innoviva (INVA) reported Net Income towards Common Stockholders of $186.6 million for Q1 2026, up 500.44% on a YoY basis from $31.1 million in Q1 2025, and up 1449.66% quarter-over-quarter from -$13.8 million in Q4 2025.
Innoviva (INVA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Innoviva has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $186.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 500.44% year-over-year to $186.6 million; the trailing twelve-month figure through Mar 2026 stood at $326.3 million (up 460.2% YoY), and the FY2025 full-year result was $271.4 million, up 1060.07% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at $186.6 million, up from -$13.8 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $265.5 million in Q3 2022, with the low at -$46.6 million in Q1 2025.
- Historically, Net Income towards Common Stockholders has averaged $38.6 million across 5 years, with a median of $1.3 million in 2023.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders tumbled 2809.77% — and 2025, when it soared 7312.78%.
- Innoviva's Net Income towards Common Stockholders stood at -$10.3 million in 2022, then jumped by 36.31% to -$6.6 million in 2023, then sank by 60.22% to -$10.5 million in 2024, then plunged by 31.16% to -$13.8 million in 2025, then jumped by 1449.66% to $186.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $186.6 million (Q1 2026), -$13.8 million (Q4 2025), and $89.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Innoviva | 1.65 Bn | 1.05 Bn | 75.83 Mn | 186.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186.56 Mn |
| Dec 31, 2025 | -13.82 Mn |
| Sep 30, 2025 | 89.92 Mn |
| Jun 30, 2025 | 63.69 Mn |
| Mar 31, 2025 | -46.59 Mn |
| Dec 31, 2024 | -10.54 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | -34.69 Mn |
| Mar 31, 2024 | 36.52 Mn |
| Dec 31, 2023 | -6.58 Mn |
| Sep 30, 2023 | 82.05 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 34.87 Mn |
| Dec 31, 2022 | -10.33 Mn |
| Sep 30, 2022 | 265.52 Mn |
| Jun 30, 2022 | 939,000.00 |
| Mar 31, 2022 | 15.77 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | 72.44 Mn |
| Jun 30, 2021 | 88.95 Mn |